Jupiter Neurosciences, Inc. Common Stock (JUNS) - Total Assets
Based on the latest financial reports, Jupiter Neurosciences, Inc. Common Stock (JUNS) holds total assets worth $2.58 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See JUNS book value for net asset value and shareholders' equity analysis.
Jupiter Neurosciences, Inc. Common Stock - Total Assets Trend (2019–2024)
This chart illustrates how Jupiter Neurosciences, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data.
Jupiter Neurosciences, Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (December 2024)
Jupiter Neurosciences, Inc. Common Stock's total assets of $2.58 Million consist of 75.0% current assets and 25.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 60.8% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Jupiter Neurosciences, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Jupiter Neurosciences, Inc. Common Stock.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Jupiter Neurosciences, Inc. Common Stock's current assets represent 75.0% of total assets in 2024, a decrease from 80.4% in 2019.
- Cash Position: Cash and equivalents constituted 60.8% of total assets in 2024, up from 20.7% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Jupiter Neurosciences, Inc. Common Stock Competitors by Total Assets
Key competitors of Jupiter Neurosciences, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233
|
China | CN¥26.08 Billion |
|
Staidson Beijing Biopharma
SHE:300204
|
China | CN¥1.26 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.64 Billion |
|
Ardelyx Inc
NASDAQ:ARDX
|
USA | $486.17 Million |
|
Xiangxue Pharmaceutical
SHE:300147
|
China | CN¥7.36 Billion |
Jupiter Neurosciences, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.65 | 0.00 | 0.13 |
| Quick Ratio | 0.65 | 0.00 | 0.13 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-886.48K | $-5.68 Million | $-3.71 Million |
Jupiter Neurosciences, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Jupiter Neurosciences, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 342.48 |
| Latest Market Cap to Assets Ratio | 2.16 |
| Asset Growth Rate (YoY) | 4074.1% |
| Total Assets | $6.20 Million |
| Market Capitalization | $13.43 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Jupiter Neurosciences, Inc. Common Stock's assets at a significant premium (2.16x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Jupiter Neurosciences, Inc. Common Stock's assets grew by 4074.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Jupiter Neurosciences, Inc. Common Stock (2019–2024)
The table below shows the annual total assets of Jupiter Neurosciences, Inc. Common Stock from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $6.20 Million | +4074.12% |
| 2023-12-31 | $148.59K | -37.02% |
| 2022-12-31 | $235.94K | -64.65% |
| 2021-12-31 | $667.38K | +21.35% |
| 2020-12-31 | $549.98K | +8803.72% |
| 2019-12-31 | $6.18K | -- |
About Jupiter Neurosciences, Inc. Common Stock
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform products for the treatment of neuroinflammation. The company develops JNS101, which is in Phase II trial for the treatment of Friedreich's Ataxia, a rare inherited disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS108 that is in Phas… Read more